7,755 results match your criteria Leukemia Research[Journal]


Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.

Leuk Res 2019 Jan 24;79:6-16. Epub 2019 Jan 24.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address:

The BCR-ABL fusion gene (BCR-ABL) has different subtypes such as p210 and p190 with p190 appear to lead to a worse prognosis. To explore the mechanism of difference in pathogenesis and prognosis in different BCR-ABL subtype-related leukemia, expression profile microarray analysis was conducted between p190 and p210 patients and verified by RT-PCR. The p21-activated kinase (PAK1) gene was chosen and regulation of the PAK1-STAT5 biological axis and its influence on proliferation and apoptosis in leukemia cells were also analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.012DOI Listing
January 2019

Chronic myeloid leukemia: Two mysteries.

Leuk Res 2019 Feb 12;79:3-5. Epub 2019 Feb 12.

Haematology Research Centre, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.003DOI Listing
February 2019

The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.

Leuk Res 2019 Feb 11;79:1-2. Epub 2019 Feb 11.

Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.02.001DOI Listing
February 2019
1 Read

Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world.

Leuk Res 2019 Jan 24. Epub 2019 Jan 24.

Laboratorio de Citometria y Biologia Molecular, Departamento Basico de Medicina, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. Electronic address:

Background: Flow cytometry (FC) is a valuable tool for the diagnosis of myelodysplastic syndromes (MDS). We present results of a survey carried out to evaluate FC current practice for MDS diagnosis in Latin America (LA), focusing on markers used and characteristics of the clinical diagnostic report. Compliance to IMDSflow recommendations was also evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.009DOI Listing
January 2019

A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.

Leuk Res 2019 Mar 24;78:45-51. Epub 2019 Jan 24.

Winship Cancer Institute of Emory University, Atlanta, GA, Georgia.

Intensive treatment for newly diagnosed acute myelogenous leukemia (ND-AML) patients are reserved for "fit" patients. While guidelines recommend evaluation of age, performance status and comorbidities, there is no consensus on the definition of "fitness" or optimal therapy for elderly AML patients. This retrospective study evaluated characteristics and survival outcomes of 274 patients (age ≥60 years) with ND-AML treated with 7 + 3 (cytarabine + an anthracycline) vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.008DOI Listing
March 2019
3 Reads

A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1 in Ph+ CML.

Leuk Res 2019 Mar 28;78:36-44. Epub 2018 Dec 28.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria. Electronic address:

In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in the context of multi-resistant BCR-ABL1 mutants, such as T315I. Treatment with ponatinib may suppress most of these mutants, including T315I, but is also associated with a high risk of clinically relevant side effects. We screened for alternative treatment options employing available tyrosine kinase inhibitors (TKI) in combination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.013DOI Listing

Should patient age be an obstacle for high-dose therapy and stem cell rescue?

Authors:
Eldad J Dann

Leuk Res 2019 Mar 25;78:34-35. Epub 2019 Jan 25.

Rambam Health Care Campus, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.010DOI Listing

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Leuk Res 2019 Mar 17;78:29-33. Epub 2019 Jan 17.

The University of Alabama at Birmingham, Birmingham, AL, United States.

Purpose: To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia.

Patients And Methods: We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolled between 2002 and 2009 into two parallel cooperative group clinical trials SWOG S0106/ECOG-ACRIN E1900. Institutions were classified as low- (LAIs) (≤ 9 enrolled patients) or high-accruing institutions (HAIs) (≥10 enrolled patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.007DOI Listing
March 2019
4 Reads

A registry-based analysis of survival outcomes in mast cell leukemia.

Leuk Res 2019 Mar 16;78:24-28. Epub 2019 Jan 16.

University of Rochester, Department of Radiation Oncology, 601 Elmwood Avenue, Rochester, NY, 14642, United States. Electronic address:

Introduction: Mast cell leukemia (MCL) is rare and carries a poor prognosis. No standard-of-care has been established. No USA registry-based analyses have examined clinical correlates of overall survival (OS) in MCL patients, thus we aimed to do this using the Surveillance, Epidemiology, and End Results (SEER) database, and the National Cancer Database (NCDB). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126193000
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2019.01.005DOI Listing
March 2019
5 Reads

STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype.

Leuk Res 2019 Mar 15;78:21-23. Epub 2019 Jan 15.

Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.004DOI Listing
March 2019
2 Reads

Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1.

Leuk Res 2019 Mar 15;78:12-20. Epub 2019 Jan 15.

Department of Cell Biology and Medical Genetics, School of Basic Medical Science, Shanxi Medical University, Taiyuan, Shanxi, China; Department of Cell and Molecular Biology, University of Rhode Island, Kingston, RI, USA. Electronic address:

Acute myeloid leukemia (AML) is a heterogeneous group of fast growing cancers of myeloid progenitor cells, for which effective treatments are still lacking. Identification of signaling inhibitors that block their proliferation could reveal the proliferative mechanism of a given leukemia cell, and provide small molecule drugs for targeted therapy for AML. In this study, kinase inhibitors that block the majority of cancer signaling pathways are evaluated for their inhibition of two AML cell lines of the M5 subtypes, CTV-1 and THP-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.006DOI Listing
March 2019
1 Read
2.351 Impact Factor

Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease.

Leuk Res 2019 Jan 6. Epub 2019 Jan 6.

Hôpital Maisonneuve-Rosemont, Division of Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cell Transplant Program, Université de Montréal, Montréal, Québec, Canada. Electronic address:

Background: Autologous hematopoietic stem cell transplantation (AHSCT) in the older population is associated with an increased risk of morbidity and mortality. Determination of the hematopoietic cell transplant comorbidity index (HCT-CI) has contributed to improve patient selection while allowing prediction of their non-relapse mortality (NRM). The goal of this study was to identify factors influencing both safety and efficacy of AHSCT in an older non-Hodgkin lymphoma (NHL) population to better select those who will benefit from this intervention in the Canadian context of a single-payer government healthcare program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.002DOI Listing
January 2019
3 Reads
2.351 Impact Factor

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

Leuk Res 2019 Feb 7;77:42-50. Epub 2019 Jan 7.

Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL, United States. Electronic address:

Despite advances in understanding the molecular pathogenesis of acute myeloid leukaemia (AML), overall survival rates remain low. The ability to predict treatment response based on individual cancer genomics using computational modeling will aid in the development of novel therapeutics and personalize care. Here, we used a combination of genomics, computational biology modeling (CBM), ex vivo chemosensitivity assay, and clinical data from 100 randomly selected patients in the Beat AML project to characterize AML sensitivity to a bromodomain (BRD) and extra-terminal (BET) inhibitor. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183047
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.010DOI Listing
February 2019
5 Reads

Involvement of pRb-E2F pathway in green tea extract-induced growth inhibition of human myeloid leukemia cells.

Leuk Res 2019 Feb 2;77:34-41. Epub 2019 Jan 2.

Department of Biology, College of Arts & Sciences, Barry University, Miami Shores, Florida 33161, USA. Electronic address:

Both inhibitory and stimulatory effect of EGCG on cancer cells have been reported, which often is linked to receptor tyrosine kinase signaling. In this study, we present evidence that green tea extract and its chemical component, Epigallocatechin-3-gallate (EGCG), inhibit growth of human myeloid leukemia cells through the regulation of pRb synthesis and formation of pRb-E2F complexes. Addition of green tea extract to the culture of TF-1a and MV4-11 myeloid leukemia cells significantly inhibited their proliferation with a substantial portion of cell death being observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.014DOI Listing
February 2019
5 Reads

Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.

Leuk Res 2019 Mar 7;78:3-11. Epub 2019 Jan 7.

Department of Medicine/Division of Hematology Oncology, University of Florida, Gainesville, FL, USA. Electronic address:

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive hematological malignancy for which optimal therapeutic approaches are poorly characterized. Using computational biology modeling (CBM) in conjunction with genomic data from cell lines and individual patients, we generated disease-specific protein network maps that were used to identify unique characteristics associated with the mutational profiles of ETP-ALL compared to non-ETP-ALL (T-ALL) cases and simulated cellular responses to a digital library of FDA-approved and investigational agents. Genomics-based classification of ETP-ALL patients using CBM had a prediction sensitivity and specificity of 93% and 87%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.003DOI Listing
March 2019
1 Read
2.351 Impact Factor

Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma.

Leuk Res 2019 Mar 3;78:1-2. Epub 2019 Jan 3.

Haematology-Pathology Research Laboratory, Odense University Hospital, Denmark; Department of Haematology, Odense University Hospital, Denmark. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.001DOI Listing
March 2019
1 Read

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.

Leuk Res 2019 Feb 24;77:30-33. Epub 2018 Dec 24.

Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Indianapolis, IN, USA; Veterans Affairs Medical Center, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.011DOI Listing
February 2019
1 Read

Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.

Leuk Res 2019 Feb 24;77:28-29. Epub 2018 Dec 24.

Department of Haematology, St. James's Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.010DOI Listing
February 2019
1 Read

Tropolone-induced effects on the unfolded protein response pathway and apoptosis in multiple myeloma cells are dependent on iron.

Leuk Res 2019 Feb 21;77:17-27. Epub 2018 Dec 21.

Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States. Electronic address:

Tropolones are naturally occurring seven-membered non-benzenoid aromatic compounds that are of interest due to their cytotoxic properties. MO-OH-Nap is a novel α-substituted tropolone that induces caspase cleavage and upregulates markers associated with the unfolded protein response (UPR) in multiple myeloma (MM) cells. Given previous reports that tropolones may function as iron chelators, we investigated the effects of MO-OH-Nap, as well as the known iron chelator deferoxamine (DFO), in MM cells in the presence or absence of supplemental iron. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.007DOI Listing
February 2019

A novel entity of acute myeloid leukaemia with recurrent RARG-rearrangement resembling acute promyelocytic leukaemia.

Leuk Res 2019 Feb 23;77:14-16. Epub 2018 Dec 23.

Department of Hematology& Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183050
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.12.009DOI Listing
February 2019
3 Reads

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

Leuk Res 2019 Feb 28;77:8-13. Epub 2018 Dec 28.

University of Rochester Medical Center, Department of Pathology, Hematopathology Unit and James P. Wilmot Cancer Institute, Rochester, NY, USA.

In patients with myelodysplastic syndromes (MDS) the impact of the percentage of erythroid precursors in the bone marrow has been the subject of considerable debate, especially with regard to prognosis. We examined the prognostic impact of the percentage of erythroid cells in the bone marrow (bmery) in 2453 primary untreated MDS patients in a retrospective multi-center analysis. Bmery were quantified in bone marrow smears at the time of diagnosis and were correlated with overall survival (OS) and AML evolution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.012DOI Listing
February 2019
2 Reads

Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma.

Leuk Res 2019 Feb 22;77:5-7. Epub 2018 Dec 22.

Unit of Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.008DOI Listing
February 2019
2.351 Impact Factor

Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.

Leuk Res 2019 Feb 19;77:1-4. Epub 2018 Dec 19.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Institute for Translational Epidemiology and Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.006DOI Listing
February 2019
1 Read

Transplantation for TP53 mutant MDS: Room for improvement.

Authors:
Dries Deeren

Leuk Res 2019 Jan 14;76:82-83. Epub 2018 Dec 14.

Department of haematology, AZ Delta, Roeselare, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.004DOI Listing
January 2019

The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.

Leuk Res 2019 Jan 11;76:76-81. Epub 2018 Dec 11.

Department of Hematology/Oncology, Odette Cancer Center, Sunnybrook Health Sciences Centre, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address:

Background: Severe thrombocytopenia affects 10% of patients with myelodysplastic syndrome (MDS) and is associated with poor outcomes. The role for prophylactic platelet transfusions in the outpatient setting is unknown.

Objective/methods: To audit treatments, bleeding rates, and transfusion requirements of patients with MDS and persistent severe thrombocytopenia (PST) registered in a prospective MDS registry at our center. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.12.002DOI Listing
January 2019
8 Reads

MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Leuk Res 2019 Jan 4;76:70-75. Epub 2018 Dec 4.

Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Germline mutation in GATA2 can lead to GATA2 deficiency characterized by a complex multi-system disorder that can present with many manifestations including variable cytopenias, bone marrow failure, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), and severe immunodeficiency. Penetrance and expressivity within families is often variable. There is a spectrum of bone marrow disease in symptomatic cytopenic patients ranging from hypocellular marrows without overt dysplasia to those with definitive MDS, AML, or chronic myelomonocytic leukemia. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340496PMC
January 2019
6 Reads

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

Leuk Res 2019 Jan 4;76:65-69. Epub 2018 Dec 4.

Dipartimento di Biotecnologie Cellulari ed Ematologia, Università Sapienza, Roma, Italy.

Few data are available on the treatment with DFX in patients with transfusion dependent Ph- Myeloproliferative Neoplasms in fibrotic phase. Here we report 48MPNpatients and iron overload treated with DFX. Starting DFX dose was 20 mg/Kg in 23 patients, 15 mg/Kg in 20 patientsand 10 mg/Kg in 5 patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.012DOI Listing
January 2019
10 Reads

Rituximab maintenance in elderly patients with follicular lymphoma.

Authors:
Carla Casulo

Leuk Res 2019 Jan 28;76:96-97. Epub 2018 Oct 28.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.10.014DOI Listing
January 2019
1 Read

Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma.

Leuk Res 2019 Jan 15;76:58-64. Epub 2018 Dec 15.

Laboratory Oncology Unit, Dr. B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Complex Chromosomal Rearrangements (CCRs) are increasingly being reported as genetic risk factors of clinical significance in cancer owing to their identification using high resolution whole genome profiling technologies. This study employed high resolution CGH + SNP microarrays for whole genome copy number variations (CNV) profiling and identified CCRs in 11/107(10%) newly diagnosed Multiple Myeloma (MM) patients. Six patients exhibited Chromothripsis (CTH) among seven chromosomes that were confirmed with automated CTLPscanner web tool and; five cases displayed chromoplexy (CPL) which involved multiple chromosomes. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183049
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.12.005DOI Listing
January 2019
10 Reads
2.351 Impact Factor

Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study.

Leuk Res 2019 Jan 4;76:53-57. Epub 2018 Dec 4.

Hematology Department, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.

Introduction: Transfusion-dependent anemia and iron overload are associatedwith reduced survival in myelodysplastic syndrome (MDS). This cross-sectional study aimed to evaluate the prevalence of hepatic and cardiac overload in patients with MDS as measured by T2* magnetic resonance imaging (MRI), and its correlation with survival.

Methods: MDS or chronic myelomonocytic leukemia patients had iron overload evaluated by T2* MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.001DOI Listing
January 2019

Germline CEBPA mutations in Korean patients with acute myeloid leukemia.

Leuk Res 2019 Jan 11;76:84-86. Epub 2018 Dec 11.

Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.003DOI Listing
January 2019
1 Read
2.351 Impact Factor

Comparison of F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkin's lymphoma.

Leuk Res 2019 Jan 5;76:48-52. Epub 2018 Dec 5.

Hematology, Department of Translation and Precision Medicine, "Sapienza" University of Rome, Italy; Hematology Unit, S. Maria Goretti Hospital, AUSL Latina, Italy. Electronic address:

We compared 2-[fluorine-18] fluoro-2-deoxy-d-glucose PET-CT and contrast-enhanced computed tomography (CECT) in 62 consecutive patients with newly diagnosed Hodgkin Lymphoma (HL), aiming to provide evidences that may spare CECT from the staging procedures of HL patients. Among a total of 1448 nodal sites examined, disease involvement was detected in 232 (16%) and 280 (19.3%) nodal areas by CECT and PET-CT, respectively (P < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.018DOI Listing
January 2019
2 Reads

Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?

Leuk Res 2019 Jan 27;76:39-47. Epub 2018 Nov 27.

Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.

Flow-cytometric detection of now termed measurable residual disease (MRD) in acute myeloid leukemia (AML) has proven to have an independent prognostic impact. In a previous multicenter study we developed protocols to accurately define leukemia-associated immunophenotypes (LAIPs) at diagnosis. It has, however, not been demonstrated whether the use of the defined LAIPs in the same multicenter setting results in a high concordance between centers in MRD assessment. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.014DOI Listing
January 2019
13 Reads

Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.

Leuk Res 2019 Jan 28;76:33-38. Epub 2018 Nov 28.

Clinica Ematologica, Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Integrata, Udine, Italy.

Background: The hypomethylating agent Decitabine (DAC) is a valuable treatment option in acute myeloid leukemia (AML), particularly in elderly patients (pts) not suitable for intensive chemotherapy (CHT). However, limited data are available about efficacy and safety of DAC in clinical practice.

Patients And Methods: We retrospectively reviewed data of 104 AML pts treated with DAC in eight Italian Hematological Centers from 2015 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.015DOI Listing
January 2019
4 Reads

Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience.

Leuk Res 2019 Jan 29;76:29-32. Epub 2018 Nov 29.

Hospices Civils de Lyon, Department of Hematology, Lyon-Sud Hospital, Pierre-Bénite, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183048
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.016DOI Listing
January 2019
2 Reads

Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.

Leuk Res 2019 Jan 27;76:87-93. Epub 2018 Nov 27.

Leukemia Research Institute, The Catholic University of Korea, Seoul, Republic of Korea; Catholic Hematology Hospital, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address:

To analyze the pattern of multiple mutations detected by Sanger sequencing (SS), we performed subcloning sequencing using 218 samples from 45 patients with tyrosine kinase inhibitor resistant chronic myeloid leukemia. At the first time of multiple mutation detection by SS (baseline), a total of 19 major mutations from 45 samples were detected; these mutations were found in the following order: T315I (68.9%), E255 K (33. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.10.019DOI Listing
January 2019
1 Read
2.351 Impact Factor

Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia?

Leuk Res 2019 Jan 22;76:94-95. Epub 2018 Nov 22.

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.011DOI Listing
January 2019
1 Read

Ocular manifestations in acute lymphoblastic leukemia: A five-year cohort study of pediatric patients.

Leuk Res 2019 Jan 29;76:24-28. Epub 2018 Nov 29.

Department of Medicine, Federal University of Sergipe, Aracaju, Sergipe, Brazil.

Objective: To characterize ocular manifestations (OM) of pediatric patients treating for acute lymphoblastic leukemia (ALL) and to evaluate whether they are associated with well-described predictive risk factors for relapse, protocol (1999 or 2009), gender and cerebrospinal fluid infiltration.

Methods: A prospective cohort study was conducted in children and adolescents with ALL from January 2013 to December 2017. The patients underwent ophthalmologic evaluations before starting treatment (D0), on the eighth day (D8), at the 28th day (D28), and at six months (D6 months). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.017DOI Listing
January 2019
4 Reads

Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.

Leuk Res 2019 Jan 17;76:15-23. Epub 2018 Nov 17.

Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen University, Aachen, Germany. Electronic address:

Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leukemia patients further supports the importance of a minimally deleted region composed of seven genes potentially involved in leukemogenesis: GKAP1, KIF27, C9ORF64, HNRNPK, RMI1, SLC28A3 and NTRK2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.007DOI Listing
January 2019
1 Read

Anatomical site as a parameter in the predictive model of diffuse large B cell lymphoma.

Authors:
David Kaplan

Leuk Res 2019 Jan 14;76:112-113. Epub 2018 Nov 14.

Case Western Reserve University, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.005DOI Listing
January 2019
1 Read

An evolving technology for an evolving disease: A commentary on NGS-based MRD evaluation in B-ALL.

Leuk Res 2019 Jan 16;76:105-106. Epub 2018 Nov 16.

University of Rochester Hematopathology Pathology and Laboratory Medicine Rochester, NY, 14642, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.009DOI Listing
January 2019

In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment.

Leuk Res 2019 Jan 16;76:11-14. Epub 2018 Nov 16.

Departamento de Química, Universidade Federal de Santa Maria, 97105-900, Santa Maria, RS, Brazil. Electronic address:

In this work, we investigated the stability of arsenic trioxide (ATO) used in leukemia treatment, encapsulated with nanoliposome, with the aid of ultrasound treatment. Stability studies of As species were followed by liquid chromatography-inductively coupled plasma mass spectrometry (LC-ICP-MS), allowing for the detection of the conversion of low amounts of As(III) to As(V) or the formation of other As species. The influence of storage temperature and time on ATO was evaluated. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183046
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.008DOI Listing
January 2019
11 Reads

A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.

Leuk Res 2019 Jan 13;76:1-10. Epub 2018 Nov 13.

Hospital Universitari i Politècnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain. Electronic address:

Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and cytarabine (CYT) 3 + 7 induction and the leukemic chemosensitivity measured by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.006DOI Listing
January 2019
8 Reads

Novel therapeutics in the treatment of hairy cell leukemia variant.

Leuk Res 2018 Dec 5;75:58-60. Epub 2018 Nov 5.

University of Missouri, 1 Hospital Dr, McHaney Hall, Columbia, MO 65212, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.002DOI Listing
December 2018
1 Read

Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.

Leuk Res 2018 Dec 13;75:50-57. Epub 2018 Nov 13.

Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan; Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Atypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) are rare BCR-ABL1 fusion gene-negative myeloid neoplasms with a predominance of neutrophils. Since no standard therapeutic strategy currently exists for these diseases, we retrospectively evaluated the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for aCML and CNL. Data from 14 aCML and 5 CNL patients as their diagnoses were collected using a nationwide survey. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183046
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.003DOI Listing
December 2018
10 Reads

Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology.

Leuk Res 2018 Dec 12;75:45-49. Epub 2018 Nov 12.

Medicine A, Rabin Medical Center, Petah-Tikva, Israel; Institute of Hematology, Davidoff Cancer Center, Israel; Sackler School of Medicine, Tel-Aviv, Israel. Electronic address:

Systemic Lupus Erythematosus (SLE), a well recognized systemic autoimmune disease is associated with an increased risk of malignancies, particularly lymphoma. Various studies have shown this risk to be as high as 4-7-fold compared to the general population. The pathogenesis of lymphoma in patients with SLE is still not well understood. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183046
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.004DOI Listing
December 2018
13 Reads

Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.

Leuk Res 2018 Dec 3;75:36-44. Epub 2018 Nov 3.

Department of Pediatrics, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan. Electronic address:

Although recent advances in chemotherapy have markedly improved outcome of acute lymphoblastic leukemia (ALL), infantile ALL with MLL gene rearrangements (MLL+ALL) is refractory to chemotherapy. We have shown that specific cytokines FLT3 ligand and TGFβ1 both of which are produced from bone marrow stromal cells synergistically induced MLL+ALL cells into chemo-resistant quiescence, and that treatment of MLL+ALL cells with inhibitors against FLT3 and/or TGFβ1 receptor partially but significantly converts them toward chemo-sensitive. In the present study, we showed that MLL+ALL cells expressed CXCR4 and CXCR7, both receptors for the same chemokine stromal cell derived factor-1 (SDF-1), but their biological events were differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes and particularly exerted an opposite effect for determining chemo-sensitivity of MLL+ALL cells; enhancement via the SDF-1/CXCR4 axis vs. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183046
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.11.001DOI Listing
December 2018
17 Reads

Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.

Leuk Res 2018 Dec 25;75:29-35. Epub 2018 Oct 25.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY, USA.

Acute myeloid leukemia (AML) in older patients is often associated with biologic and clinical characteristics that predict poor outcomes to cytarabine and anthracycline based induction chemotherapy (IC). The impact of hypomethylating agents (HMA) in the treatment of these high-risk patients is unknown. Here we retrospectively examined the remission rates and survival outcomes of 201 newly diagnosed patients ≥60 years old with therapy-related (t-AML), secondary (s-AML), or AML with myelodysplasia-related changes (AML-MRC). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126183044
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2018.10.011DOI Listing
December 2018
12 Reads

The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities.

Leuk Res 2018 Dec 2;75:23-28. Epub 2018 Nov 2.

Institute of Pathology, Medical Faculty, University of Belgrade, Dr Subotica 1, 11000, Belgrade, Serbia. Electronic address:

This study explores cytomorphologic features and their predictive role for early identification of acute myeloid leukemia (AML) with morphological distinctive recurrent cytogenetic abnormalities (RCA): t(15;17), t(8;21) and inv(16)/t(16;16). We retrospectively evaluated 396 de novo AML cases, diagnosed and treated at single institution, between 2013-2017. Specific cytomorphologic features suggesting distinctive AML-RCA were revealed at diagnosis in 62 (15. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.10.017DOI Listing
December 2018
4 Reads

A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.

Leuk Res 2018 Dec 3;75:15-22. Epub 2018 Nov 3.

Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY, United States.

B cell acute lymphoblastic leukemia (B ALL) is a genetically heterogeneous neoplasm often demonstrating extensive subclone diversity within each patient's disease. The immunoglobulin heavy chain (IGH) locus is a marker of clonal variation in B ALL due to its intrinsic role in B lymphocyte development and its diverse Vh(D)Jh rearrangement patterns. B ALL IGH evolution may contribute to limitations in minimal residual disease (MRD) monitoring methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.10.018DOI Listing
December 2018